Novo Holdings raises stakes on Zealand Pharma competitor – joins million-dollar investment
Once again, Novo Ventures posts millions of dollars in newly founded spinout company Vectivbio, which is developing a treatment for short bowel syndrome. This time, the Danish venture fund joins a USD 110m investment in the firm, which plans to challenge Zealand Pharma with its drug.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Recently founded spinout company Vectivbio has landed a USD 110m investment from both existing investors and newcomers.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
